

Category	#	Recommendation	Strength of recommendation	Quality of evidence	% agreement
GENERAL	Q1	Title: Shared decision making	Strong	Very Low	100%
	Q2	Title: Initiation criteria for biologic or advanced therapy	Strong	High	100%
	Q3	Title: Local approval, access, and implementation considerations	Conditional	Very Low	94,12%
	Q4	Title: First-line biologic options	Strong	High	94,10%
ANTI-TNF	Q5	Title: First-line anti-TNF therapy	Strong	High	82,35%
	Q6	Title: Infliximab as second-line anti-TNF therapy	Conditional	Moderate	58,82%
	Q7	Title: Therapeutic drug monitoring for anti-TNF therapy	Conditional	Low	70,59%
	Q8	Title: Off-label dose escalation of anti-TNF therapy	Conditional	Low	88,24%
	Q9	Title: Certolizumab and golimumab as third-line anti-TNF therapies	Conditional	Low	41,18%
	Q10	Title: Etanercept should not be used for HS	Strong	Moderate	82,35%
	Q11	Title: Perioperative use of biologic therapy in HS surgery	Conditional	Moderate	100,00%
ANTI-IL-17	Q12	Title: Secukinumab and bimekizumab as first-line IL-17i therapies	Strong	High	94,12%
	Q13	Title: Brodalumab as a second-line IL-17i therapy	Conditional	Low	58,82%
ANTI-IL-1	Q14	Title: Anakinra as an alternative treatment option for selected patients with HS	Conditional	Moderate	58,82%
	Q15	Title: Canakinumab as a second-choice anti-IL-1 alternative for selected patients with HS	Conditional	Very Low	35,29%
ANTI-IL-12/23	Q16	Title: Ustekinumab as an alternative treatment for selected patients with HS	Conditional	Low	41,18%
ANTI-IL-23	Q17	Title: IL-23 inhibitors as a 2nd line alternative treatment in the IL12/23 pathways for selected	Conditional	Very Low	70,59%
JAKi	Q18	Title: Upadacitinib as an alternative treatment for selected patients with HS	Conditional	Moderate	94,12%